MindMed To Include MDMA to Research Portfolio

Neuro-pharmaceutical and psychedelics research company Mind Medicine Inc. MMED MMEDF announced Wednesday the inclusion of the psychoactive compound MDMA to its R&D pipeline.

The move comes as part of the company’s exclusive collaboration agreement with the University Hospital Basel’s Liechti Lab

A Potential in Combining MDMA with Other Psychedelics

“We see an amazing opportunity to optimize the subjective effect profiles of known psychedelics like LSD and MDMA to potentially make a more advanced and comfortable therapeutic experience for the patient,” JR Rahn, CEO of MindMed, told Benzinga.

University of Basel Professor Dr. Matthias Liechti, who was one of the original scientific researchers to discover the mechanism of action of MDMA in the 1990s, said that his lab has generated a large amount of data on the pharmacokinetics, pharmacogenetics and safety of MDMA in over 10 years of clinical research.

MindMed will leverage Liechti’s experience in leading multiple clinical trials of the safety profile of MDMA to explore ways to develop psychedelic therapies combining MDMA and LSD.

“We are most interested in how MDMA can be combined with other medicines or psychedelics and plan to focus our R+D funding on developing this concept further for patients,” said Rahn.

MDMA was granted “Breakthrough Therapy” designation by the FDA in 2017, revealing the agency’s consideration that MDMA-assisted psychotherapy may have a meaningful advantage over available medications for PTSD.

Market News and Data brought to you by Benzinga APIs
Posted In: CannabisHealth CareMarketsGeneralDr. Matthias LiechtiJR RahnLSDMDMAMindMedPsychedelics
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

The Benzinga Cannabis Capital Conference is coming to Florida

The Benzinga Cannabis Capital Conference is returning to Florida, in a new venue in Hollywood, on April 16 and 17, 2024. The two-day event at The Diplomat Beach Resort will be a chance for entrepreneurs, both large and small, to network, learn and grow. Renowned for its trendsetting abilities and influence on the future of cannabis, mark your calendars – this conference is the go-to event of the year for the cannabis world.

Get your tickets now on bzcannabis.com – Prices will increase very soon!